Novel Pulmonary Hypertension Drug From Bayer Shows Modest Promise In Phase 3 Trials

A new drug appears to have promising– but not game-changing– effects in people with two forms of pulmonary hypertension. Riociguat, a soluble guanylate cyclase stimulator under development by Bayer, is thought to have vasodilating, antiproliferative and antifibrotic effects.

Results of two phase 3 placebo-controlled trials were published today in the New England Journal of Medicine. CHEST-1 studied the clinical impact of riociguat in 262 patients with chronic thromboembolic pulmonary hypertension; PATENT-1 studied the the drug in 443 patients with pulmonary arterial hypertension.

Click here to read the full story on Forbes, including a comment from pulmonary hypertension expert John Ryan.


Ball-and-stick model of the riociguat molecule...



  1. […] to @Slate’s Carlos Danger Name Generator” and Richard Roeper writing, “My sexting pseudonym is Armando Catastrophe, according to @Slate’s Carlos Danger Name […]

Speak Your Mind